{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:15:15Z","timestamp":1788491715594,"version":"build-2803163510"},"reference-count":40,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BTT"],"DOI":"10.2147\/btt.s285610","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T23:44:36Z","timestamp":1609890276000},"page":"1-15","source":"Crossref","is-referenced-by-count":11,"title":["Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Timothy","family":"Fitzgerald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8378-5186","authenticated-orcid":true,"given":"Richard","family":"Melsheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s12325-015-0256-7","volume":"32","author":"Vangeli","year":"2015","journal-title":"Adv Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","volume":"37","author":"Hunter","year":"2017","journal-title":"Rheumatol Int"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.cgh.2016.10.039","volume":"15","author":"Shivashankar","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrgastro.2009.238","volume":"7","author":"Hanauer","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref6","unstructured":"Janssen Pharmaceutical Companies. REMICADE (Infliximab) Highlights of Prescribing Information; 2018."},{"key":"ref7","first-page":"139","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics"},{"key":"ref8","unstructured":"Food and Drug Administration (FDA). Biosimilar and interchangeable products. 2017; https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-and-interchangeable-products. Accessed December 17, 2019."},{"key":"ref9","unstructured":"CELLTRION, Inc. INFLECTRA\u00ae (Infliximab-Dyyb) Highlights of Prescribing Information; 2019."},{"key":"ref10","unstructured":"Amgen Inc. AVSOLA (Infliximab-Axxq) Highlights of Prescribing Information; 2019."},{"key":"ref11","unstructured":"Samsung Bioepis Co. RENFLEXIS (Infliximab-Abda) Highlights of Prescribing Information; 2019."},{"key":"ref12","unstructured":"Pfizer Ireland Pharmaceuticals. IXIFI (Infliximab-Qbtx) Highlights of Prescribing Information; 2020."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/03007995.2019.1571296","volume":"35","author":"Teeple","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.clinthera.2017.03.005","volume":"39","author":"Wolf","year":"2017","journal-title":"Clin Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"Glintborg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jbspin.2017.10.003","volume":"85","author":"Scherlinger","year":"2018","journal-title":"Joint Bone Spine"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet (London, England)"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2017-211741","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.semarthrit.2017.10.002","volume":"47","author":"Avouac","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14712598.2016.1198765","volume":"16","author":"Gentileschi","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/art.40324","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/CLEP.S147175","volume":"9","author":"Lund","year":"2017","journal-title":"Clin Epidemiol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","volume":"7","author":"Fleischmann","year":"2020","journal-title":"Rheumatol Ther"},{"key":"ref25","unstructured":"Mahmmod S, Schultheiss J, Mahmmod N, Tan A, Dijkstra G, Fidder H. P1809 - Reverse switching to originator infliximab may be considered in patients with inflammatory bowel diseases experiencing new side effects or loss of response after switching to a CT-P13 biosimilar. Paper presented at: United European Gastroenterology Week 2019."},{"key":"ref26","author":"Ho","year":"2020","journal-title":"BioDrugs"},{"key":"ref27","first-page":"835","volume":"76","author":"Phillips","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5414\/CP203474","volume":"57","author":"Reuber","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref29","first-page":"127","volume":"12","author":"Yazici","year":"2018","journal-title":"Biologics"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.31138\/mjr.30.1.69","volume":"30","author":"Madenidou","year":"2019","journal-title":"Mediterranean J Rheumatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/annrheumdis-2016-210356","volume":"76","author":"Alten","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjz203.455","volume":"14","author":"Mahmmod","year":"2020","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"A581","DOI":"10.1016\/j.jval.2016.09.1351","volume":"19","author":"Brown","year":"2016","journal-title":"Value Health"},{"key":"ref34","author":"Liu","year":"2019","journal-title":"Adv Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1756284819858052","DOI":"10.1177\/1756284819858052","volume":"12","author":"Guerra Veloz","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/00365521.2018.1463391","volume":"53","author":"Hoivik","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/jcm8070956","volume":"8","author":"Kaltsonoudis","year":"2019","journal-title":"J Clin Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40744-017-0085-z","volume":"4","author":"Rezk","year":"2017","journal-title":"Rheumatol Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/03007995.2018.1560221","volume":"35","author":"Teeple","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3899\/jrheum.091461","volume":"85","author":"El-Gabalawy","year":"2010","journal-title":"J Rheumatol Suppl"}],"container-title":["Biologics: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=65416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=65416","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T22:43:08Z","timestamp":1724280188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/switching-and-discontinuation-patterns-among-patients-stable-on-origin-peer-reviewed-article-BTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":40,"URL":"https:\/\/doi.org\/10.2147\/btt.s285610","relation":{},"ISSN":["1177-5491"],"issn-type":[{"value":"1177-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}